Ignite Creation Date:
2025-12-24 @ 4:09 PM
Ignite Modification Date:
2025-12-27 @ 7:01 PM
Study NCT ID:
NCT04898166
Status:
COMPLETED
Last Update Posted:
2021-10-26
First Post:
2021-05-11
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19).
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D000505', 'term': 'Alopecia'}, {'id': 'D000086382', 'term': 'COVID-19'}], 'ancestors': [{'id': 'D007039', 'term': 'Hypotrichosis'}, {'id': 'D006201', 'term': 'Hair Diseases'}, {'id': 'D012871', 'term': 'Skin Diseases'}, {'id': 'D017437', 'term': 'Skin and Connective Tissue Diseases'}, {'id': 'D020763', 'term': 'Pathological Conditions, Anatomical'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}, {'id': 'D011024', 'term': 'Pneumonia, Viral'}, {'id': 'D011014', 'term': 'Pneumonia'}, {'id': 'D012141', 'term': 'Respiratory Tract Infections'}, {'id': 'D007239', 'term': 'Infections'}, {'id': 'D014777', 'term': 'Virus Diseases'}, {'id': 'D018352', 'term': 'Coronavirus Infections'}, {'id': 'D003333', 'term': 'Coronaviridae Infections'}, {'id': 'D030341', 'term': 'Nidovirales Infections'}, {'id': 'D012327', 'term': 'RNA Virus Infections'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'mahanumsyed8@gmail.com', 'phone': '03033901112', 'title': 'Syeda Mahanum Ali', 'organization': 'Jinnah postgraduate medical centre'}, 'certainAgreement': {'piSponsorEmployee': True}}, 'adverseEventsModule': {'timeFrame': 'From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condition(from mask/bag to ventilator) or death from any cause, assessed up to 4 months', 'description': "Our participants are hospitalized COVID-19 patients. Their adverse events are categorised as on oxygen mask/bag,nasal cannula, ventilator or death.\n\nOther non serious adverse events are zero because all of our participants were having covid19 so they faced it's symptom and no any other adverse event separately", 'eventGroups': [{'id': 'EG000', 'title': '300 Participants Diagnosed Case of Hospitalized COVID-19 With or Without Androgenetic Alopecia.', 'description': '300 Participants diagnosed case of hospitalized COVID-19. 220 males and 80 females. Presence or absence of androgenetic alopecia be noted in males and females. Severity of androgeneic throught be noted throught Hamilton norwood score and ludwig score, respectively. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.', 'otherNumAtRisk': 300, 'deathsNumAtRisk': 300, 'otherNumAffected': 0, 'seriousNumAtRisk': 300, 'deathsNumAffected': 87, 'seriousNumAffected': 300}], 'seriousEvents': [{'term': '87 male and female participants death', 'stats': [{'groupId': 'EG000', 'numAtRisk': 300, 'numAffected': 87}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Male and female participants on ventilator', 'stats': [{'groupId': 'EG000', 'numAtRisk': 300, 'numAffected': 56}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Male and female participants on oxygen mask/bag', 'stats': [{'groupId': 'EG000', 'numAtRisk': 300, 'numAffected': 69}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}, {'term': 'Male and female participants on nasal cannula', 'stats': [{'groupId': 'EG000', 'numAtRisk': 300, 'numAffected': 88}], 'organSystem': 'Infections and infestations', 'assessmentType': 'SYSTEMATIC_ASSESSMENT'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Androgenetic Alopecia Frequency in Participants.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '220', 'groupId': 'OG000'}, {'value': '80', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': '220 Hospitalized Participants Diagnosed Case of COVID-19.', 'description': '220 hospitalised male participants diagnosed case of COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught Hamilton norwood scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.'}, {'id': 'OG001', 'title': '80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19', 'description': '80 hospitalized female Participants diagnosed case of hospitalized COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught ludwig scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.'}], 'classes': [{'categories': [{'title': 'With androgenetic alopecia', 'measurements': [{'value': '209', 'groupId': 'OG000'}, {'value': '37', 'groupId': 'OG001'}]}, {'title': 'Without androgenetic alopecia', 'measurements': [{'value': '11', 'groupId': 'OG000'}, {'value': '43', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 1 of admission', 'description': 'Frequency of Androgenetic alopecia in patients be noted.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Severity of Androgenetic Alopecia in Patients', 'denoms': [{'units': 'Participants', 'counts': [{'value': '220', 'groupId': 'OG000'}, {'value': '37', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': '220 Hospitalised Male Participants Diagnosed Case of COVID-19.', 'description': '220 hospitalised male participants diagnosed case of COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught Hamilton norwood scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.'}, {'id': 'OG001', 'title': '80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19.', 'description': '80 hospitalized female Participants diagnosed case of hospitalized COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught ludwig scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death'}], 'classes': [{'categories': [{'title': 'Mild to moderate', 'measurements': [{'value': '43', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}, {'title': 'Severe', 'measurements': [{'value': '177', 'groupId': 'OG000'}, {'value': '28', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Day 1 of admission', 'description': 'Severity of androgenetic alopecia be measured using Hamilton and norwood scale (HNS) less than 3 or 3-7.\n\nIn females using ludwig scale: less than 2 or 2-3. Hamilton norwood score: Minimum value 1, maximum value 7. Ludwig score: minimum 0, maximum 3 Mild to moderate: HNS \\<3/ Ludwig \\<2 Severe: HNS 3-7/ ludwig 2-3', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': '300 Participants Mean Age', 'denoms': [{'units': 'Participants', 'counts': [{'value': '300', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': '300 Participants Diagnosed Case of Hospitalized COVID-19. Mean Age be Noted', 'description': '300 Participants diagnosed case of hospitalized COVID-19. Mean age be noted in both males and females'}], 'classes': [{'categories': [{'measurements': [{'value': '53.06', 'spread': '13.495', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 of admission', 'description': 'Age of the patient is very important to co-relate with disease outcome and severity of Androgenetic alopecia', 'unitOfMeasure': 'years', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '220', 'groupId': 'OG000'}, {'value': '80', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': '220 Hospitalised Male Participants Diagnosed Case of COVID-19.', 'description': '220 hospitalised male participants diagnosed case of COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught Hamilton norwood scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.'}, {'id': 'OG001', 'title': '80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19.', 'description': '80 hospitalized female Participants diagnosed case of hospitalized COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught ludwig scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death'}], 'classes': [{'categories': [{'title': 'Participants on mask/bag with age 20-40years', 'measurements': [{'value': '15', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}, {'title': 'Participants on mask/bag with age >40-60 years', 'measurements': [{'value': '13', 'groupId': 'OG000'}, {'value': '18', 'groupId': 'OG001'}]}, {'title': 'Participants on mask/bag with age >60years', 'measurements': [{'value': '13', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}, {'title': 'Participants on Nasal cannula with age 20-40years', 'measurements': [{'value': '15', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}, {'title': 'Participants on nasal cannula with age >40-60 years', 'measurements': [{'value': '37', 'groupId': 'OG000'}, {'value': '12', 'groupId': 'OG001'}]}, {'title': 'Participants on nasal cannula with age >60years', 'measurements': [{'value': '20', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}, {'title': 'Participants on ventilator with age 20-40years', 'measurements': [{'value': '4', 'groupId': 'OG000'}, {'value': '11', 'groupId': 'OG001'}]}, {'title': 'Participants on ventilator with age >40-60 years', 'measurements': [{'value': '16', 'groupId': 'OG000'}, {'value': '15', 'groupId': 'OG001'}]}, {'title': 'Participants on ventilator with age >60years', 'measurements': [{'value': '10', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}, {'title': 'Participants death with age 20-40 years', 'measurements': [{'value': '7', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}, {'title': 'Participants death with age >40-60 years', 'measurements': [{'value': '33', 'groupId': 'OG000'}, {'value': '6', 'groupId': 'OG001'}]}, {'title': 'Participants death with age >60years', 'measurements': [{'value': '37', 'groupId': 'OG000'}, {'value': '0', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condtion(from mask/bag to ventilator) or death from any cause, assessed up to 4 months', 'description': 'Outcome of participants suffering from covid-19 with respect to age group as better outcomes: oxygen mask/bag or nasal cannula Worst outcomes: ventilator or death', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Disease Outcome as Assessed by Severity of Androgeneic Alopecia in Males', 'denoms': [{'units': 'Participants', 'counts': [{'value': '220', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': '220 Hospitalised Male Subjects. Their Disease Outcomes in Relation to Severity of AGA', 'description': '220 hospitalised male participants diagnosed case of COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of Androgenetic alopecia be noted throught Hamilton norwood scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death. Their disease outcomes in relation to severity of AGA'}], 'classes': [{'categories': [{'title': 'Patients on nasal cannula with HNS <3', 'measurements': [{'value': '20', 'groupId': 'OG000'}]}, {'title': 'Patients on nasal cannula with HNS 3-7', 'measurements': [{'value': '52', 'groupId': 'OG000'}]}, {'title': 'Patients on mask/bag with HNS <3', 'measurements': [{'value': '14', 'groupId': 'OG000'}]}, {'title': 'Patients on mask/bag with HNS 3-7', 'measurements': [{'value': '27', 'groupId': 'OG000'}]}, {'title': 'Patients on ventilator with HNS <3', 'measurements': [{'value': '5', 'groupId': 'OG000'}]}, {'title': 'Patients on ventilator with HNS 3-7', 'measurements': [{'value': '25', 'groupId': 'OG000'}]}, {'title': 'Patients death with HNS <3', 'measurements': [{'value': '4', 'groupId': 'OG000'}]}, {'title': 'Patients death with HNS 3-7', 'measurements': [{'value': '73', 'groupId': 'OG000'}]}]}], 'analyses': [{'pValue': '0.000', 'groupIds': ['OG000'], 'statisticalMethod': 'Chi-squared', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Chi-square value 18.90 and its asymptotic significance .000'}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condtion(from mask/bag to ventilator) or death from any cause, assessed up to 4 months', 'description': 'Covid-19 disease outcome assessed by Severity of androgenetic alopecia to find out their correlation', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females', 'denoms': [{'units': 'Participants', 'counts': [{'value': '80', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': '80 Hospitalised Female Participants. Their Disease Outcomes in Relation to Severity of AGA', 'description': '80 hospitalised female participants diagnosed case of COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught ludwig scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death. Their disease outcomes in relation to severity of AGA'}], 'classes': [{'categories': [{'title': 'Female participants on mask/bag with no androgenetic alopecia', 'measurements': [{'value': '9', 'groupId': 'OG000'}]}, {'title': 'Female participants on mask/bag with ludwig scale <2', 'measurements': [{'value': '3', 'groupId': 'OG000'}]}, {'title': 'Female participants on mask/bag with ludwig scale 2-3', 'measurements': [{'value': '4', 'groupId': 'OG000'}]}, {'title': 'Female participants on nasal cannula without androgenetic alopecia', 'measurements': [{'value': '17', 'groupId': 'OG000'}]}, {'title': 'Female participants on nasal cannula with ludwig scale <2', 'measurements': [{'value': '3', 'groupId': 'OG000'}]}, {'title': 'Female participants on nasal cannula with ludwig scale 2-3', 'measurements': [{'value': '8', 'groupId': 'OG000'}]}, {'title': 'Female participants on ventilator with no androgenetic alopecia', 'measurements': [{'value': '14', 'groupId': 'OG000'}]}, {'title': 'Female participants on ventilator with ludwig scale <2', 'measurements': [{'value': '3', 'groupId': 'OG000'}]}, {'title': 'Female participants on ventilator with ludwig scale 2-3', 'measurements': [{'value': '9', 'groupId': 'OG000'}]}, {'title': 'Female participants death with no androgenetic alopecia', 'measurements': [{'value': '3', 'groupId': 'OG000'}]}, {'title': 'Female participants death with ludwig scale <2', 'measurements': [{'value': '0', 'groupId': 'OG000'}]}, {'title': 'Female participants death with ludwig scale 2-3', 'measurements': [{'value': '7', 'groupId': 'OG000'}]}]}], 'analyses': [{'pValue': '0.081', 'groupIds': ['OG000'], 'statisticalMethod': 'Chi-squared', 'nonInferiorityType': 'SUPERIORITY', 'statisticalComment': 'Chi-square value 7.544 and its asymptotic significance .273'}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condtion(from mask/bag to ventilator) or death from any cause, assessed up to 4 months', 'description': 'Covid-19 disease outcome assessed by Severity of androgenetic alopecia to find out their correlation', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females.', 'denoms': [{'units': 'Participants', 'counts': [{'value': '37', 'groupId': 'OG000'}, {'value': '43', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': '37 Hospitalised Female Participants of COVID-19 With Androgenetic Alopecia', 'description': '37 hospitalised female participants diagnosed case of COVID-19 presence of absence of androgenetic alopecia influencing outcome be noted as patient on mask/bag, nasal cannula, ventilator or death with respec to aget'}, {'id': 'OG001', 'title': '43 Hospitalised Female Participants of COVID-19 Without Androgenetic Alopecia With Respect to Age', 'description': '43 hospitalised female participants diagnosed case of COVID-19 with androgenetic alopecia. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death with respect to age'}], 'classes': [{'categories': [{'title': 'Age 20-40yrs: nasal cannula', 'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '4', 'groupId': 'OG001'}]}, {'title': 'Age >40-60yrs: nasal cannula', 'measurements': [{'value': '7', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}, {'title': 'Age >60yrs nasal cannula', 'measurements': [{'value': '00', 'groupId': 'OG000'}, {'value': '00', 'groupId': 'OG001'}]}, {'title': 'Age 20-40yrs: mask/bag', 'measurements': [{'value': '3', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}]}, {'title': 'Age >40-60yrs: mask/bag', 'measurements': [{'value': '8', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}, {'title': 'Age >60yrs mask/bag', 'measurements': [{'value': '00', 'groupId': 'OG000'}, {'value': '00', 'groupId': 'OG001'}]}, {'title': 'Age 20-40yrs: ventilator', 'measurements': [{'value': '6', 'groupId': 'OG000'}, {'value': '5', 'groupId': 'OG001'}]}, {'title': 'Age >40-60yrs: ventilator', 'measurements': [{'value': '6', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}, {'title': 'Age >60yrs: ventilator', 'measurements': [{'value': '00', 'groupId': 'OG000'}, {'value': '00', 'groupId': 'OG001'}]}, {'title': 'Age 20-40yrs: death', 'measurements': [{'value': '3', 'groupId': 'OG000'}, {'value': '1', 'groupId': 'OG001'}]}, {'title': 'Age >40-60yrs: death', 'measurements': [{'value': '4', 'groupId': 'OG000'}, {'value': '2', 'groupId': 'OG001'}]}, {'title': 'Age >60yrs: death', 'measurements': [{'value': '00', 'groupId': 'OG000'}, {'value': '00', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condtion(from mask/bag to ventilator) or death from any cause, assessed up to 4 months', 'description': 'It is to find out how severily disease outcomes can be affected due to androgeneic alopecia by age accordingly.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males', 'denoms': [{'units': 'Participants', 'counts': [{'value': '43', 'groupId': 'OG000'}, {'value': '177', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': '43 Hospitalised Male Participants Diagnosed Case of COVID-19 With HNS <3.', 'description': '43 hospitalised male participants diagnosed case of COVID-19 with HNS \\<3. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught Hamilton norwood scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death with respect to age'}, {'id': 'OG001', 'title': '177 Hospitalised Male Participants Diagnosed Case of COVID-19 With HNS >3-7', 'description': '177 hospitalised male participants diagnosed case of COVID-19 with HNS 3-7. Severity of androgeneic be noted throught Hamilton norwood scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death with respect to age'}], 'classes': [{'categories': [{'title': 'Nasal cannula Age 20-40yrs', 'measurements': [{'value': '4', 'groupId': 'OG000'}, {'value': '11', 'groupId': 'OG001'}]}, {'title': 'Nasal cannula age >40-60yrs', 'measurements': [{'value': '10', 'groupId': 'OG000'}, {'value': '27', 'groupId': 'OG001'}]}, {'title': 'Nasal cannula age >60yrs', 'measurements': [{'value': '6', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}]}, {'title': 'Mask/bag age 20-40yrs', 'measurements': [{'value': '6', 'groupId': 'OG000'}, {'value': '9', 'groupId': 'OG001'}]}, {'title': 'Mask/bag age >40-60yrs', 'measurements': [{'value': '5', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}, {'title': 'Mask/bag age >60yrs', 'measurements': [{'value': '3', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}, {'title': 'Ventilator age 20-40yrs', 'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '3', 'groupId': 'OG001'}]}, {'title': 'Ventilator age >40-60yrs', 'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '14', 'groupId': 'OG001'}]}, {'title': 'Ventilator age >60yr', 'measurements': [{'value': '2', 'groupId': 'OG000'}, {'value': '8', 'groupId': 'OG001'}]}, {'title': 'Death age 20-40yrs', 'measurements': [{'value': '0', 'groupId': 'OG000'}, {'value': '7', 'groupId': 'OG001'}]}, {'title': 'Death age >40-60yrs', 'measurements': [{'value': '1', 'groupId': 'OG000'}, {'value': '32', 'groupId': 'OG001'}]}, {'title': 'Death age >60yrs', 'measurements': [{'value': '3', 'groupId': 'OG000'}, {'value': '34', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condtion(from mask/bag to ventilator) or death from any cause, assessed up to 4 months', 'description': 'It is to find out how severily disease outcomes can be affected due to androgeneic alopecia by age accordingly.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'PRIMARY', 'title': 'Hospital Disease Outcome in 300 Subjects. Having 220 Males and 80 Females', 'denoms': [{'units': 'Participants', 'counts': [{'value': '220', 'groupId': 'OG000'}, {'value': '80', 'groupId': 'OG001'}]}], 'groups': [{'id': 'OG000', 'title': '220 Hospitalized Participants Diagnosed Case of COVID-19.', 'description': '220 hospitalised male participants diagnosed case of COVID-19. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.'}, {'id': 'OG001', 'title': '80 Hospitalized Female Participants Diagnosed Case of Hospitalized COVID-19', 'description': '80 hospitalized female Participants diagnosed case of hospitalized COVID-19. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.'}], 'classes': [{'categories': [{'title': 'Mask/bag', 'measurements': [{'value': '41', 'groupId': 'OG000'}, {'value': '28', 'groupId': 'OG001'}]}, {'title': 'Nasal cannula', 'measurements': [{'value': '72', 'groupId': 'OG000'}, {'value': '16', 'groupId': 'OG001'}]}, {'title': 'Ventilator usage', 'measurements': [{'value': '30', 'groupId': 'OG000'}, {'value': '26', 'groupId': 'OG001'}]}, {'title': 'Death', 'measurements': [{'value': '77', 'groupId': 'OG000'}, {'value': '10', 'groupId': 'OG001'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Disease outcome during this 4 month duration of study.', 'description': 'Hospital disease outcome as mask, cannnula, ventilator or death in 300 subjects. Having 220 males and 80 Females', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants', 'denoms': [{'units': 'Participants', 'counts': [{'value': '300', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': '300 Participants Diagnosed Case of Hospitalized COVID-19 Outcome in Relation to Comorbidities', 'description': '300 Participants diagnosed case of hospitalized COVID-19. 220 males and 80 females. Presence or absence of comorbidities. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.'}], 'classes': [{'categories': [{'title': 'participant on nasal cannula with no comorbidity', 'measurements': [{'value': '29', 'groupId': 'OG000'}]}, {'title': 'participant on nasal cannula with history of smoking', 'measurements': [{'value': '6', 'groupId': 'OG000'}]}, {'title': 'participant on nasal cannula with history of ischemic heart disease', 'measurements': [{'value': '4', 'groupId': 'OG000'}]}, {'title': 'participant on nasal cannula with history of diabetes mellitus', 'measurements': [{'value': '12', 'groupId': 'OG000'}]}, {'title': 'participant on nasal cannula with history of hypertension', 'measurements': [{'value': '15', 'groupId': 'OG000'}]}, {'title': 'participant on nasal cannula with history of obesity', 'measurements': [{'value': '8', 'groupId': 'OG000'}]}, {'title': 'participant on nasal cannula with history of chronic kidney disease', 'measurements': [{'value': '5', 'groupId': 'OG000'}]}, {'title': 'participant on nasal cannula with history of multiple comorbidities', 'measurements': [{'value': '9', 'groupId': 'OG000'}]}, {'title': 'participant on mask/bag with no comorbidity', 'measurements': [{'value': '20', 'groupId': 'OG000'}]}, {'title': 'Participants on mask/bag with history of smoking', 'measurements': [{'value': '6', 'groupId': 'OG000'}]}, {'title': 'participant on mask/bag with history of history of ischemic heart disease', 'measurements': [{'value': '1', 'groupId': 'OG000'}]}, {'title': 'participant on mask/bag with history of diabetes mellitus', 'measurements': [{'value': '15', 'groupId': 'OG000'}]}, {'title': 'participant on mask/bag with history of hypertension', 'measurements': [{'value': '8', 'groupId': 'OG000'}]}, {'title': 'participant on mask/bag with obesity', 'measurements': [{'value': '6', 'groupId': 'OG000'}]}, {'title': 'participant on mask/bag with history of chronic kidney disease', 'measurements': [{'value': '4', 'groupId': 'OG000'}]}, {'title': 'participant on mask/bag with history of multiple comorbidities', 'measurements': [{'value': '9', 'groupId': 'OG000'}]}, {'title': 'participant on ventilator with no comorbidity', 'measurements': [{'value': '17', 'groupId': 'OG000'}]}, {'title': 'Participants on Ventilator with history of smoking', 'measurements': [{'value': '1', 'groupId': 'OG000'}]}, {'title': 'participant on ventilator with history of ischemic heart disease', 'measurements': [{'value': '2', 'groupId': 'OG000'}]}, {'title': 'participant on ventilator with history of diabetes mellitus', 'measurements': [{'value': '7', 'groupId': 'OG000'}]}, {'title': 'participant on ventilator with history of hypertension', 'measurements': [{'value': '10', 'groupId': 'OG000'}]}, {'title': 'participant on ventilator with history of obesity', 'measurements': [{'value': '6', 'groupId': 'OG000'}]}, {'title': 'participant on Ventilator with history of chronic kidney disease', 'measurements': [{'value': '1', 'groupId': 'OG000'}]}, {'title': 'participant on ventilator with history of multiple comorbidities', 'measurements': [{'value': '12', 'groupId': 'OG000'}]}, {'title': 'Participants death with no comorbidity', 'measurements': [{'value': '26', 'groupId': 'OG000'}]}, {'title': 'participant death with history of smoking', 'measurements': [{'value': '1', 'groupId': 'OG000'}]}, {'title': 'participant death: history of ischemic heart disease', 'measurements': [{'value': '9', 'groupId': 'OG000'}]}, {'title': 'participant death with history diabetes mellitus', 'measurements': [{'value': '18', 'groupId': 'OG000'}]}, {'title': 'participant death with history of hypertension', 'measurements': [{'value': '18', 'groupId': 'OG000'}]}, {'title': 'participant death with history of obesity', 'measurements': [{'value': '1', 'groupId': 'OG000'}]}, {'title': 'participant death with history of kidney disease', 'measurements': [{'value': '5', 'groupId': 'OG000'}]}, {'title': 'participant death with history of multiple comorbidities', 'measurements': [{'value': '9', 'groupId': 'OG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'timeFrame': 'Date of randomization until upto 4 months', 'description': 'Comorbidities in patients suffering from covid-19 is of great value as it affects disease outcome.number of patients suffrring from comorbidities eg: diabetes mellitus, smoking, hypertension, ischemic heart disease, chronic kidney disease, obesity.', 'unitOfMeasure': 'Participants', 'reportingStatus': 'POSTED'}, {'type': 'SECONDARY', 'title': 'Disease Duration of COVID-19', 'denoms': [{'units': 'Participants', 'counts': [{'value': '300', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': '300 Participants Diagnosed Case of Hospitalized COVID-19 Disease Duration', 'description': '300 Participants diagnosed case of hospitalized COVID-19 mean and standard deviation of disease duration.'}], 'classes': [{'categories': [{'measurements': [{'value': '11.79', 'spread': '5.727', 'groupId': 'OG000'}]}]}], 'paramType': 'MEAN', 'timeFrame': 'Day 1 of admission, till disease outcome in upto 4 months', 'description': 'Duration of symptoms patients experiencing from the onset of symptoms till outcome.', 'unitOfMeasure': 'Days', 'dispersionType': 'Standard Deviation', 'reportingStatus': 'POSTED'}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': '220 Hospitalized Male Participants Diagnosed Case of COVID-19.', 'description': '220 hospitalised male participants diagnosed case of COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught Hamilton norwood scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.'}, {'id': 'FG001', 'title': '80 Hospitalized Female Participants Diagnosed Case of COVID-19.', 'description': '80 hospitalized female Participants diagnosed case of hospitalized COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught ludwig scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '220'}, {'groupId': 'FG001', 'numSubjects': '80'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '220'}, {'groupId': 'FG001', 'numSubjects': '80'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '0'}, {'groupId': 'FG001', 'numSubjects': '0'}]}]}], 'recruitmentDetails': '300 participants at COVID-19 isolation unit jinnah postgraduate medical centre karachi.', 'preAssignmentDetails': '* 300 participants signed consent for participation.\n* 300 participants assigned for the study.'}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '220', 'groupId': 'BG000'}, {'value': '80', 'groupId': 'BG001'}, {'value': '300', 'groupId': 'BG002'}]}], 'groups': [{'id': 'BG000', 'title': '220 Hospitalized Male Participants Diagnosed Case of COVID-19.', 'description': '220 hospitalized male Participants diagnosed case of COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught Hamilton norwood scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.'}, {'id': 'BG001', 'title': '80 Hospitalized Female Participants Diagnosed Case of COVID-19', 'description': '80 hospitalized female Participants diagnosed case of COVID-19. Presence or absence of androgenetic alopecia be noted. Severity of androgeneic be noted throught ludwig scale. Severity of COVID-19 and outcome be noted as patient on mask/bag, nasal cannula, ventilator or death.'}, {'id': 'BG002', 'title': 'Total', 'description': 'Total of all reporting groups'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '53.39', 'spread': '14.928', 'groupId': 'BG000'}, {'value': '52.17', 'spread': '8.391', 'groupId': 'BG001'}, {'value': '53.06', 'spread': '13.5', 'groupId': 'BG002'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Age, Customized', 'classes': [{'title': 'Between 20 to 40 years', 'categories': [{'measurements': [{'value': '41', 'groupId': 'BG000'}, {'value': '29', 'groupId': 'BG001'}, {'value': '70', 'groupId': 'BG002'}]}]}, {'title': 'Between >40 to 60 years', 'categories': [{'measurements': [{'value': '99', 'groupId': 'BG000'}, {'value': '51', 'groupId': 'BG001'}, {'value': '150', 'groupId': 'BG002'}]}]}, {'title': '>60 years', 'categories': [{'measurements': [{'value': '80', 'groupId': 'BG000'}, {'value': '00', 'groupId': 'BG001'}, {'value': '80', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '00', 'groupId': 'BG000'}, {'value': '80', 'groupId': 'BG001'}, {'value': '80', 'groupId': 'BG002'}]}, {'title': 'Male', 'measurements': [{'value': '220', 'groupId': 'BG000'}, {'value': '00', 'groupId': 'BG001'}, {'value': '220', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Ethnicity (NIH/OMB)', 'classes': [{'categories': [{'title': 'Hispanic or Latino', 'measurements': [{'value': '00', 'groupId': 'BG000'}, {'value': '00', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}, {'title': 'Not Hispanic or Latino', 'measurements': [{'value': '220', 'groupId': 'BG000'}, {'value': '80', 'groupId': 'BG001'}, {'value': '300', 'groupId': 'BG002'}]}, {'title': 'Unknown or Not Reported', 'measurements': [{'value': '00', 'groupId': 'BG000'}, {'value': '00', 'groupId': 'BG001'}, {'value': '0', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Region of Enrollment', 'classes': [{'title': 'Pakistan', 'categories': [{'measurements': [{'value': '220', 'groupId': 'BG000'}, {'value': '80', 'groupId': 'BG001'}, {'value': '300', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}, {'title': 'Comorbidities', 'classes': [{'title': 'Smoking', 'categories': [{'measurements': [{'value': '14', 'groupId': 'BG000'}, {'value': '2', 'groupId': 'BG001'}, {'value': '16', 'groupId': 'BG002'}]}]}, {'title': 'Ischemic heart disease', 'categories': [{'measurements': [{'value': '12', 'groupId': 'BG000'}, {'value': '4', 'groupId': 'BG001'}, {'value': '16', 'groupId': 'BG002'}]}]}, {'title': 'Diabetes mellitus', 'categories': [{'measurements': [{'value': '35', 'groupId': 'BG000'}, {'value': '17', 'groupId': 'BG001'}, {'value': '52', 'groupId': 'BG002'}]}]}, {'title': 'Hypertension', 'categories': [{'measurements': [{'value': '34', 'groupId': 'BG000'}, {'value': '17', 'groupId': 'BG001'}, {'value': '51', 'groupId': 'BG002'}]}]}, {'title': 'Obesity', 'categories': [{'measurements': [{'value': '15', 'groupId': 'BG000'}, {'value': '6', 'groupId': 'BG001'}, {'value': '21', 'groupId': 'BG002'}]}]}, {'title': 'Chronic kidney disease', 'categories': [{'measurements': [{'value': '10', 'groupId': 'BG000'}, {'value': '5', 'groupId': 'BG001'}, {'value': '15', 'groupId': 'BG002'}]}]}, {'title': 'Multiple comorbidities', 'categories': [{'measurements': [{'value': '20', 'groupId': 'BG000'}, {'value': '19', 'groupId': 'BG001'}, {'value': '39', 'groupId': 'BG002'}]}]}, {'title': 'No comorbidity', 'categories': [{'measurements': [{'value': '82', 'groupId': 'BG000'}, {'value': '10', 'groupId': 'BG001'}, {'value': '92', 'groupId': 'BG002'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}]}}, 'documentSection': {'largeDocumentModule': {'largeDocs': [{'date': '2021-03-31', 'size': 115326, 'label': 'Study Protocol and Statistical Analysis Plan', 'hasIcf': False, 'hasSap': True, 'filename': 'Prot_SAP_000.pdf', 'typeAbbrev': 'Prot_SAP', 'uploadDate': '2021-07-13T17:39', 'hasProtocol': True}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'OTHER', 'observationalModel': 'OTHER'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 300}, 'targetDuration': '4 Months', 'patientRegistry': True}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2020-12-01', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2021-10', 'completionDateStruct': {'date': '2021-03-31', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2021-10-23', 'studyFirstSubmitDate': '2021-05-11', 'resultsFirstSubmitDate': '2021-07-18', 'studyFirstSubmitQcDate': '2021-05-21', 'lastUpdatePostDateStruct': {'date': '2021-10-26', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2021-07-29', 'studyFirstPostDateStruct': {'date': '2021-05-24', 'type': 'ACTUAL'}, 'resultsFirstPostDateStruct': {'date': '2021-08-02', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2021-03-31', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Androgenetic Alopecia Frequency in Participants.', 'timeFrame': 'Day 1 of admission', 'description': 'Frequency of Androgenetic alopecia in patients be noted.'}, {'measure': 'Severity of Androgenetic Alopecia in Patients', 'timeFrame': 'Day 1 of admission', 'description': 'Severity of androgenetic alopecia be measured using Hamilton and norwood scale (HNS) less than 3 or 3-7.\n\nIn females using ludwig scale: less than 2 or 2-3. Hamilton norwood score: Minimum value 1, maximum value 7. Ludwig score: minimum 0, maximum 3 Mild to moderate: HNS \\<3/ Ludwig \\<2 Severe: HNS 3-7/ ludwig 2-3'}, {'measure': '300 Participants Mean Age', 'timeFrame': 'Day 1 of admission', 'description': 'Age of the patient is very important to co-relate with disease outcome and severity of Androgenetic alopecia'}, {'measure': 'Disease Outcome as Assessed by Number of Participants Experiencing Better or Worst Outcome With Respect to Age Group.', 'timeFrame': 'From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condtion(from mask/bag to ventilator) or death from any cause, assessed up to 4 months', 'description': 'Outcome of participants suffering from covid-19 with respect to age group as better outcomes: oxygen mask/bag or nasal cannula Worst outcomes: ventilator or death'}, {'measure': 'Disease Outcome as Assessed by Severity of Androgeneic Alopecia in Males', 'timeFrame': 'From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condtion(from mask/bag to ventilator) or death from any cause, assessed up to 4 months', 'description': 'Covid-19 disease outcome assessed by Severity of androgenetic alopecia to find out their correlation'}, {'measure': 'Disease Outcome be Assessed by Severity of Androgenetic Alopecia in Females', 'timeFrame': 'From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condtion(from mask/bag to ventilator) or death from any cause, assessed up to 4 months', 'description': 'Covid-19 disease outcome assessed by Severity of androgenetic alopecia to find out their correlation'}, {'measure': 'Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Females.', 'timeFrame': 'From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condtion(from mask/bag to ventilator) or death from any cause, assessed up to 4 months', 'description': 'It is to find out how severily disease outcomes can be affected due to androgeneic alopecia by age accordingly.'}, {'measure': 'Covid-19 Disease Outcomes Correlating With Severity of Androgenetic Alopecia and Age in Males', 'timeFrame': 'From date of randomization until the date of clinical improvement (discharge, from ventilator to mask/nasal cannula) or worsening of condtion(from mask/bag to ventilator) or death from any cause, assessed up to 4 months', 'description': 'It is to find out how severily disease outcomes can be affected due to androgeneic alopecia by age accordingly.'}, {'measure': 'Hospital Disease Outcome in 300 Subjects. Having 220 Males and 80 Females', 'timeFrame': 'Disease outcome during this 4 month duration of study.', 'description': 'Hospital disease outcome as mask, cannnula, ventilator or death in 300 subjects. Having 220 males and 80 Females'}], 'secondaryOutcomes': [{'measure': 'Comorbidities Including Diabetes Mellitus, Smoking, Hypertension, Ischemic Heart Disease, Chronic Kidney Disease, Obesity in Participants', 'timeFrame': 'Date of randomization until upto 4 months', 'description': 'Comorbidities in patients suffering from covid-19 is of great value as it affects disease outcome.number of patients suffrring from comorbidities eg: diabetes mellitus, smoking, hypertension, ischemic heart disease, chronic kidney disease, obesity.'}, {'measure': 'Disease Duration of COVID-19', 'timeFrame': 'Day 1 of admission, till disease outcome in upto 4 months', 'description': 'Duration of symptoms patients experiencing from the onset of symptoms till outcome.'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Covid19', 'Androgenetic alopecia'], 'conditions': ['Androgenetic Alopecia', 'Coronavirus Disease 2019', 'Covid19', 'Male Pattern Baldness', 'Female Pattern Baldness', 'COVID-19 Pneumonia']}, 'referencesModule': {'references': [{'pmid': '32237190', 'type': 'BACKGROUND', 'citation': 'Goren A, McCoy J, Wambier CG, Vano-Galvan S, Shapiro J, Dhurat R, Washenik K, Lotti T. What does androgenetic alopecia have to do with COVID-19? An insight into a potential new therapy. Dermatol Ther. 2020 Jul;33(4):e13365. doi: 10.1111/dth.13365. Epub 2020 Apr 8. No abstract available.'}, {'pmid': '33098701', 'type': 'BACKGROUND', 'citation': 'Muller Ramos P, Ianhez M, Amante Miot H. Alopecia and grey hair are associated with COVID-19 Severity. Exp Dermatol. 2020 Dec;29(12):1250-1252. doi: 10.1111/exd.14220. Epub 2020 Nov 18. No abstract available.'}, {'pmid': '32301221', 'type': 'BACKGROUND', 'citation': 'Goren A, Vano-Galvan S, Wambier CG, McCoy J, Gomez-Zubiaur A, Moreno-Arrones OM, Shapiro J, Sinclair RD, Gold MH, Kovacevic M, Mesinkovska NA, Goldust M, Washenik K. A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain - A potential clue to the role of androgens in COVID-19 severity. J Cosmet Dermatol. 2020 Jul;19(7):1545-1547. doi: 10.1111/jocd.13443. Epub 2020 Apr 23.'}, {'pmid': '32446821', 'type': 'BACKGROUND', 'citation': 'Wambier CG, Vano-Galvan S, McCoy J, Gomez-Zubiaur A, Herrera S, Hermosa-Gelbard A, Moreno-Arrones OM, Jimenez-Gomez N, Gonzalez-Cantero A, Fonda-Pascual P, Segurado-Miravalles G, Shapiro J, Perez-Garcia B, Goren A. Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The "Gabrin sign". J Am Acad Dermatol. 2020 Aug;83(2):680-682. doi: 10.1016/j.jaad.2020.05.079. Epub 2020 May 22.'}, {'pmid': '32333494', 'type': 'BACKGROUND', 'citation': 'McCoy J, Wambier CG, Vano-Galvan S, Shapiro J, Sinclair R, Ramos PM, Washenik K, Andrade M, Herrera S, Goren A. Racial variations in COVID-19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti-androgens a potential treatment for COVID-19? J Cosmet Dermatol. 2020 Jul;19(7):1542-1543. doi: 10.1111/jocd.13455. Epub 2020 Jun 14. No abstract available.'}, {'pmid': '32707256', 'type': 'BACKGROUND', 'citation': 'Lee J, Yousaf A, Fang W, Kolodney MS. Male balding is a major risk factor for severe COVID-19. J Am Acad Dermatol. 2020 Nov;83(5):e353-e354. doi: 10.1016/j.jaad.2020.07.062. Epub 2020 Jul 22.'}, {'pmid': '32735970', 'type': 'BACKGROUND', 'citation': 'Wambier CG, Vano-Galvan S, McCoy J, Pai S, Dhurat R, Goren A. Androgenetic alopecia in COVID-19: Compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign. J Am Acad Dermatol. 2020 Dec;83(6):e453-e454. doi: 10.1016/j.jaad.2020.07.099. Epub 2020 Jul 29.'}], 'seeAlsoLinks': [{'url': 'https://pubmed.ncbi.nlm.nih.gov/32237190/', 'label': 'What does androgenetic alopecia have to do with COVID-19? An insight into a potential new therapy'}, {'url': 'https://pubmed.ncbi.nlm.nih.gov/33098701/', 'label': 'Alopecia and grey hair are associated with COVID-19 Severity'}, {'url': 'https://pubmed.ncbi.nlm.nih.gov/32301221/', 'label': 'A preliminary observation: Male pattern hair loss among hospitalized COVID-19 patients in Spain - A potential clue to the role of androgens in COVID-19 severity'}, {'url': 'https://pubmed.ncbi.nlm.nih.gov/32446821/', 'label': 'Androgenetic alopecia present in the majority of patients hospitalized with COVID-19: The "Gabrin sign"'}, {'url': 'https://pubmed.ncbi.nlm.nih.gov/32333494/', 'label': 'Racial variations in COVID-19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti-androgens a potential treatment for COVID-19?'}, {'url': 'https://pubmed.ncbi.nlm.nih.gov/32707256/', 'label': 'Male balding is a major risk factor for severe COVID-19'}, {'url': 'https://pubmed.ncbi.nlm.nih.gov/32735970/', 'label': 'Androgenetic alopecia in COVID-19: Compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign'}]}, 'descriptionModule': {'briefSummary': 'Coronavirus disease 2019 (COVID-19) can cause variable symptoms ranging from mild common cold-like symptoms to severe life threatening pneumonia. Recent studies show severe outcomes of COVID-19 patients specially in males who suffer from androgenetic alopecia, would be significant and is of particular interest of this study and could help further support the hypothesis that anti-androgen therapy might represents an additional potential intervention against severe COVID-19.', 'detailedDescription': 'INTRODUCTION: An outbreak of Corona virus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-coV-2) occurred in Wuhan city, Hubei province, China in December 2019. Belonging to the family Beta-coronavirus, this virus can cause variable symptoms ranging from mild common cold-like symptoms to severe life threatening pneumonia. Numerous cases of new onset of skin lesions in COVID-19 patients are spreading across the globe. There are also some reports of aggravation of prior skin disorders. While severe COVID-19 symptoms and high mortality primarily manifested in older adults specially adult males, this sexual dimorphism in the severity of COVID-19 patients predisposed possibly due to increased androgen levels particularly in males suffering from androgenetic alopecia (AGA) would be significant and is of particular interest of this study and could help further support the hypothesis that anti-androgen therapy might represents an additional potential intervention against severe COVID-19.\n\nOBJECTIVE: Association of Androgenetic alopecia and severity of Coronavirus disease 2019 (COVID-19).\n\nPLACE OF STUDY: COVID-19 isolation unit of Jinnah postgraduate medical center (JPMC) Karachi, Sindh province, Pakistan.\n\nRESEARCH METHODOLOGY: This study will be conducted on patients admitted in COVID-19 isolation unit of JPMC Karachi. Permission from the institutional ethical review committee will be taken prior to conduction of study, demographic data and written informed consent will be taken from every patient. Sample size of study would be 300 hospitalized patients of COVID-19. Detailed history and examination of patients including be conducted in COVID-19 patients. Scoring of AGA be evaluated using Hamilton-Norwood scale (HNS) in men and Ludwig scale in female. Severity of the COVID-19 be measured by COVID severity score (A-DROP). Study is aimed to evaluate association of AGA and severity of COVID-19, frequency of AGA in covid 19 and whether the lung involvement correlates with the severity of AGA or whether the proportion of AGA is higher in intensive care/fatal COVID-19.\n\nDATA ANALYSIS: Data will be analysed using SPSS version 23 registered for Microsoft windows. Mean and standard deviation will be calculated for expression of quantitative variables like age, weight, duration of disease symptoms. Frequencies and percentages will be calculated for the qualitative variables like gender, co-morbidities, frequency and severity of AGA, disease outcome and AGA associated with severity of COVID-19. Effect modifiers like age, gender, weight, co-morbidities, duration of symptoms will be controlled through stratification. Post-stratification will be recalculated and chi-square test will be applied. P-value of \\<0.05% will be considered as significant.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '100 Years', 'minimumAge': '20 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'Hospitalised diagnosed covid-19 patients with or without comorbidities. Irrespective of disease duration. Intensity and frequency of androgenetic alopecia, disease outcome be noted in these patients.', 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Hospitalized patients of diagnosed covid-19 age \\> 20years\n* with or without androgenetic alopecia\n* with or without comorbidities\n* irrespective of disease duration -\n\nExclusion Criteria:\n\n* none'}, 'identificationModule': {'nctId': 'NCT04898166', 'briefTitle': 'Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19).', 'organization': {'class': 'OTHER_GOV', 'fullName': 'Jinnah Postgraduate Medical Centre'}, 'officialTitle': 'Association of Androgenetic Alopecia and Severity of Coronavirus Disease 2019 (COVID-19)', 'orgStudyIdInfo': {'id': 'NO.F.2-81/2021-GEN/56923/JPMC'}}, 'contactsLocationsModule': {'locations': [{'zip': '75510', 'city': 'Karachi', 'state': 'Sindh', 'country': 'Pakistan', 'facility': 'Jinnah postgraduate medical center', 'geoPoint': {'lat': 24.8608, 'lon': 67.0104}}], 'overallOfficials': [{'name': 'Rabia Ghafoor, MBBS, FCPS, SCE-Derm(MRCP-UK)', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Jinnah Postgraduate Medical Centre'}, {'name': 'Syeda Mahanum Ali, MBBS, Postgraduate Trainee', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Jinnah Postgraduate Medical Centre'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Syeda Mahanum Ali', 'class': 'OTHER_GOV'}, 'responsibleParty': {'type': 'SPONSOR_INVESTIGATOR', 'investigatorTitle': 'Postgraduate trainee dermatology', 'investigatorFullName': 'Syeda Mahanum Ali', 'investigatorAffiliation': 'Jinnah Postgraduate Medical Centre'}}}}